Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, Huang YC, Shen HL. Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report. World J Clin Cases 2022; 10(4): 1286-1290 [PMID: 35211561 DOI: 10.12998/wjcc.v10.i4.1286]
Corresponding Author of This Article
Hai-Li Shen, Chief Doctor, Department of Rheumatology, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou 730030, Gansu Province, China. shenhl_523@163.com
Research Domain of This Article
Immunology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 6, 2022; 10(4): 1286-1290 Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1286
Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
Juan Zhang, Xin Wang, Jing-Jing Tian, Rong Zhu, Rui-Xue Duo, Yi-Chen Huang, Hai-Li Shen
Juan Zhang, Xin Wang, Jing-Jing Tian, Rong Zhu, Rui-Xue Duo, Hai-Li Shen, Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China
Yi-Chen Huang, Second Clinical Medical College, Lanzhou University, Lanzhou 730030, Gansu Province, China
Author contributions: Shen HL and Zhang J designed the research and wrote the paper; Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, and Huang YC collected all the data related to the case report; Shen HL supervised the report; all authors have read and approved the final manuscript.
Supported bythe Lanzhou Science and Technology Plan Project, No. 2018-3-48; Lanzhou Talent Innovation and Entrepreneurship Project, No. 2019-RC-35; and 2019 Special Fund for Doctoral Training of Lanzhou University Second Hospital, No. YJS-BD-15.
Informed consent statement: Written informed consent was obtained from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Li Shen, Chief Doctor, Department of Rheumatology, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou 730030, Gansu Province, China. shenhl_523@163.com
Received: July 29, 2021 Peer-review started: July 29, 2021 First decision: October 25, 2021 Revised: November 3, 2021 Accepted: December 23, 2021 Article in press: December 23, 2021 Published online: February 6, 2022 Processing time: 179 Days and 5.2 Hours
Abstract
BACKGROUND
Primary Sjögren's syndrome (pSS) concomitant with autoimmune hemolytic anemia (AIHA) but without eye and mouth dryness is exceedingly rare. Iguratimod (IGU) has been widely used in the treatment of pSS. However, there are few reports about the application of IGU in pSS concomitant with AIHA.
CASE SUMMARY
Here, we present the case of a patient with pSS concomitant with AIHA but without eye and mouth dryness. The patient was initially diagnosed with hyperplastic anemia and AIHA while pSS was missed, and was finally diagnosed with pSS concomitant with AIHA. The patient was treated with IGU along with prednisone and hydroxychloroquine, and her hemoglobin, reticulocytes and IgG returned to normal levels.
CONCLUSION
IGU was effective for and well tolerated by our patient with pSS concomitant with AIHA, and may be a promising therapy for the treatment of this disease.
Core Tip: Primary Sjögren's syndrome (pSS) concomitant with autoimmune hemolytic anemia (AIHA) but without eye and mouth dryness is exceedingly rare. Iguratimod (IGU) has been widely used in the treatment of pSS. However, there are few reports about the application of IGU in pSS concomitant with AIHA. Here, we present the case of a patient with pSS concomitant with AIHA who was successfully treated with IGU. IGU was effective for and well tolerated by our patient with pSS concomitant with AIHA, and may be a promising therapy for treatment of this disease.
